At 12.0% CAGR, the Asia Pacific Radiopharmaceutical Theranostics Market is projected to be worth US$ 667.40 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific radiopharmaceutical theranostics market was valued at US$ 337.53 million in 2022 and is expected to reach US$ 667.40 million by 2028, registering a CAGR of 12.0% from 2022 to 2028. Rising incidence of cancer and rising application in treatment of cardiovascular disorders are the critical factors attributed to the Asia Pacific radiopharmaceutical theranostics market expansion.             

Radiopharmaceutical therapies (RPTs) involve injecting a particular radioactive drug (such as 200mCi for Lu-177-PSMA and Lu-177-DOTATATE) into all patients undergoing therapy. However, upon injection, the doses delivered to organs and absorbed qualities of drugs show notable variations. Radiopharmaceutical therapies for tumors and normal tissues depend on absorbed doses; however, variations in absorption are difficult to control. A fixed administered dosage results in the undertreatment of patients, possibly leading to cases of dose toxicity. Theranostic digital twins (TDTs) can be employed in the drug development process to overcome such limitations. The TDTs investigate optimal injected radioactive drugs among patients at the sites of injection, along with determining injection intervals and profiles, and suitable combinational radiopharmaceutical therapies. Additionally, TDTs coupled with appropriate computational tools can be used in predictive absorbed radiation dose modeling. Further, TDTs promise zero uncertainties in the clinical results generated, thus acting as a powerful tool for offering truly personalized treatments to patients. Thus, the use of TDTs in personalized radiopharmaceutical therapies provides lucrative opportunities for radiopharmaceutical theranostics market players. This is expected to drive the Asia Pacific radiopharmaceutical theranostics market during the forecast period.

On the contrary, regulatory challenges for approval of radiopharmaceutical theranostics hurdles the growth of Asia Pacific radiopharmaceutical theranostics market. 

Based on product type, the Asia Pacific radiopharmaceutical theranostics market is categorized into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The positron emission tomography (PET) tracers segment held 51.3% market share in 2022, amassing US$ 172.98 million. It is projected to garner US$ 351.18 million by 2028 to expand at 12.6% CAGR during 2022–2028.

Based on radioisotope, the Asia Pacific radiopharmaceutical theranostics market is categorized into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18 (18F), yttrium 90 (Y-90), Lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held 27.0% market share in 2022, amassing US$ 91.14 million. It is projected to garner US$ 190.14 million by 2028 to expand at 13.0% CAGR during 2022–2028.

Based on source, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held 57.9% market share in 2022, amassing US$ 195.51 million. It is projected to garner US$ 411.44 million by 2028 to expand at 13.2% CAGR during 2022–2028.

Based on application, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held 65.9% market share in 2022, amassing US$ 222.46 million. It is projected to garner US$ 445.64 million by 2028 to expand at 12.3% CAGR during 2022–2028.

Based on indication, the Asia Pacific radiopharmaceutical theranostics market is categorized into oncology, cardiology, neurology, and others. The oncology segment held 58.2% market share in 2022, amassing US$ 196.42 million. It is projected to garner US$ 402.77 million by 2028 to expand at 12.7% CAGR during 2022–2028.

Based on end user, the Asia Pacific radiopharmaceutical theranostics market is categorized into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held 34.5% market share in 2022, amassing US$ 116.33 million. It is projected to garner US$ 226.25 million by 2028 to expand at 11.7% CAGR during 2022–2028.

Based on country, the Asia Pacific radiopharmaceutical theranostics market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific.  Our regional analysis states that China captured 28.8% share of Asia Pacific radiopharmaceutical theranostics market in 2022. It was assessed at US$ 97.07 million in 2022 and is likely to hit US$ 197.75 million by 2028, exhibiting a CAGR of 12.6% during the forecast period.            

Key players dominating the Asia Pacific radiopharmaceutical theranostics market are Bayer AG; GE Healthcare Technologies Inc.; Curium; Telix Pharmaceuticals Ltd.; and Cardinal Health Inc. among others.

• In Dec 2021, Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics.
• In Dec 2021, FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com